» Articles » PMID: 28100326

[Feeding Difficulty and Developmental Delay for 8 Months and Nystagmus for 4 Months in an Infant]

Overview
Specialty Pediatrics
Date 2017 Jan 20
PMID 28100326
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare autosomal recessive hereditary disease and is a congenital metabolic disorder of neurotransmitter biosynthesis. It is mainly manifested as hypotonia, oculogyric crisis, autonomic dysfunction, and developmental delay. This article reports a boy manifested as delayed motor development, hypotonia, and oculogyric crisis. Gene screening for metabolic disorders revealed new compound heterozygous mutations, c.1063dupA (p.I355fs) and c.250A>C (p.S84R), in the exon of DDC gene. The boy had a significant increase in 3-O-methyldopa as measured by dried blood spot. Therefore, he was diagnosed with AADC deficiency. After treatment with the dopamine receptor agonist pramipexole dihydrochloride, the catechol-O-methyltransferase inhibitor entacapone, and vitamin B6, the boy showed mild improvements in hypotonia, blepharoptosis, and oculogyric crisis. Clinical physicians should enhance their ability for identifying AADC deficiency, so as to facilitate early diagnosis and treatment of this disorder. Genetic counseling for birth health and prenatal diagnosis should be performed for parents in need.

Citing Articles

Clinical Features in Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Systematic Review.

Rizzi S, Spagnoli C, Frattini D, Pisani F, Fusco C Behav Neurol. 2022; 2022:2210555.

PMID: 36268467 PMC: 9578880. DOI: 10.1155/2022/2210555.


The genetic and clinical characteristics of aromatic L-amino acid decarboxylase deficiency in mainland China.

Wen Y, Wang J, Zhang Q, Chen Y, Bao X J Hum Genet. 2020; 65(9):759-769.

PMID: 32409695 PMC: 7387242. DOI: 10.1038/s10038-020-0770-6.


Aromatic L-amino acid decarboxylase deficiency in 17 Mainland China patients: Clinical phenotype, molecular spectrum, and therapy overview.

Dai W, Lu D, Gu X, Yu Y Mol Genet Genomic Med. 2020; 8(3):e1143.

PMID: 31975548 PMC: 7057092. DOI: 10.1002/mgg3.1143.

References
1.
Mastrangelo M, Caputi C, Galosi S, Giannini M, Leuzzi V . Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mov Disord. 2013; 28(4):556-7. DOI: 10.1002/mds.25303. View

2.
Haliloglu G, Vezir E, Baydar L, Onol S, Sivri S, Coskun T . When do we need to perform a diagnostic lumbar puncture for neurometabolic diseases? Positive yield and retrospective analysis from a tertiary center. Turk J Pediatr. 2012; 54(1):52-8. View

3.
Manegold C, Hoffmann G, Degen I, Ikonomidou H, Knust A, Laass M . Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis. 2009; 32(3):371-80. DOI: 10.1007/s10545-009-1076-1. View

4.
Lee N, Chien Y, Hu M, Liu W, Chen P, Wang W . Treatment of congenital neurotransmitter deficiencies by intracerebral ventricular injection of an adeno-associated virus serotype 9 vector. Hum Gene Ther. 2013; 25(3):189-98. PMC: 3955971. DOI: 10.1089/hum.2013.170. View

5.
Chtarto A, Bockstael O, Tshibangu T, Dewitte O, Levivier M, Tenenbaum L . A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Br J Clin Pharmacol. 2013; 76(2):217-32. PMC: 3731597. DOI: 10.1111/bcp.12065. View